Journal article
T. Le, A. Yoon, Thavasyappan Thambi, C. Yun
Frontiers in Immunology, 2022
Frontiers in Immunology, 2022
Semantic Scholar
DOI
PubMedCentral
PubMed
Cite
Cite
APA
Click to copy
Le, T., Yoon, A., Thambi, T., & Yun, C. (2022). Polymeric Systems for Cancer Immunotherapy: A Review. Frontiers in Immunology.
Chicago/Turabian
Click to copy
Le, T., A. Yoon, Thavasyappan Thambi, and C. Yun. “Polymeric Systems for Cancer Immunotherapy: A Review.” Frontiers in Immunology (2022).
MLA
Click to copy
Le, T., et al. “Polymeric Systems for Cancer Immunotherapy: A Review.” Frontiers in Immunology, 2022.
BibTeX Click to copy
@article{t2022a,
title = {Polymeric Systems for Cancer Immunotherapy: A Review},
year = {2022},
journal = {Frontiers in Immunology},
author = {Le, T. and Yoon, A. and Thambi, Thavasyappan and Yun, C.}
}
Abstract
Immunotherapy holds enormous promise to create a new outlook of cancer therapy by eliminating tumors via activation of the immune system. In immunotherapy, polymeric systems play a significant role in improving antitumor efficacy and safety profile. Polymeric systems possess many favorable properties, including magnificent biocompatibility and biodegradability, structural and component diversity, easy and controllable fabrication, and high loading capacity for immune-related substances. These properties allow polymeric systems to perform multiple functions in immunotherapy, such as immune stimulants, modifying and activating T cells, delivery system for immune cargos, or as an artificial antigen-presenting cell. Among diverse immunotherapies, immune checkpoint inhibitors, chimeric antigen receptor (CAR) T cell, and oncolytic virus recently have been dramatically investigated for their remarkable success in clinical trials. In this report, we review the monotherapy status of immune checkpoint inhibitors, CAR-T cell, and oncolytic virus, and their current combination strategies with diverse polymeric systems.